Ischemia Reperfusion Injury – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Ischemia Reperfusion Injury – Drugs In Development, 2023’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury
- The report reviews pipeline therapeutics for Ischemia Reperfusion Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ischemia Reperfusion Injury therapeutics and enlists all their major and minor projects
- The report assesses Ischemia Reperfusion Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Abfero Pharmaceuticals IncAlloksys Life Sciences BV
Amyndas Pharmaceuticals LLC
Anagenics Ltd
Argenx SE
Asta Pharmaceuticals Co Ltd
Axolo Pharma Inc
Balmes Transplantation SAS
Beijing Northland Biotech Co Ltd
Bilix Co Ltd
Biogen Inc
Bolder Biotechnology Inc
Celdara Medical LLC
Cellvie Inc
CFM Pharma Holding BV
Chengdu Medical College
Corline Biomedical AB
Cypralis Ltd
Domainex Ltd
EVAS Therapeutics LLC
Faron Pharmaceuticals Oy
Flanders Institute for Biotechnology
French National Institute of Health and Medical Research
Gero LLC
Gifu University School of Medicine
Gilead Sciences Inc
Glucox Biotech AB
Glycan Therapeutics Inc
Ischemix Inc
Kansas State University
Kyoto Pharmaceutical University
Larix Bioscience LLC
Lee's Pharmaceutical Holdings Ltd
Lepton Pharmaceuticals Ltd
LUCA Science Inc
Mallinckrodt Plc
Marshall University
Monash University
Neuroene Therapeutics LLC
New Beta Innovation Ltd
New Horizons Pharma Inc
Nour Heart Therapeutics LLC
NuNerve Pty Ltd
Omeros Corp
Orion Corp
Oxitope Pharma BV
Pharmadrug Inc
PharmaTher Holdings Ltd
Pharming Group NV
Purine Pharmaceuticals Inc
Radikal Therapeutics Inc
Revive Therapeutics Ltd
Sairiyo Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Slate Bio Inc
Stanford University
Stealth BioTherapeutics Inc.
The Hospital for Sick Children
TheraSource LLC
United Therapeutics Corp
University of Exeter
University of Illinois at Chicago
University of Iowa
University of Toledo
University of Western Australia
Young Therapeutics LLC